Q4 adjusted EBITDA was in line with our estimate, but adjustments burdened net results.
Railcare avslutade året med ett kvartal där svaghet inom Entreprenad vägdes upp av en förbättring in...
Redeye comments on Invisio’s Q4-results which easily beat our forecasts while order intake was also ...
* NOI 2% y-o-y, 2.4% vs ABGSCe, 1.5% vs cons. * Value changes of -0.
CEO Joachim Samuelsson discusses the year-end report and the events of the past year, business model...
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat o...
Solteq reported its first comparable revenue growth in eight quarters, driven by the Utilities segme...
Profitability was mainly in line with our expectations and didn’t offer surprises.
Redeye leaves a short comment following OncoZenge’s announcement of having received the third tranch...
Marimekko's fourth quarter revenue missed our estimates slightly, weighed down by wholesale weakness...
Raute achieved an EBITDA margin of 15.8% in Q4’25, which it may not be able to produce again in the ...
Finnair’s Q4 earnings reached a record high especially due to efficient operations.
Redeye considers Polygiene’s Q4'25 figures to be soft, missing our expectations by 18% on top-line, ...
As anticipated, Genovis’ year-end report showcased robust top-line momentum, with sharp sales growth...
Redeye comments on Litium’s Q4, which showed solid momentum with 18% ARR growth and net sales above ...
* Sales 2% and adj. EBIT -31% vs. ABGSCe * Order intake SEK 251m, above expectations * Likely negati...
* Q4 sales SEK 18m (-14% y-o-y), -16% vs. ABGSCe * EBIT adj.
Atria reported Q4 adjusted EBIT of EUR 14.0m, 3% below LSEG Data & Analytics consensus.
Redeye is encouraged by Nekkar’s financial recovery during the fourth quarter, which posted a 30% be...
Redeye provides its initial take on Ferroamp’s Q4 numbers, which presented strong sales growth and s...